UniProt P54762 · PDB · AlphaFold · Substrate: pEY · Clone: cytoplasmichigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Bosutinib | 99.5% | 0.5% | 87.22 | 0.555 |
| 2 | Dasatinib | 99.4% | 0.6% | 87.97 | 0.699 |
| 3 | Nilotinib | 98.8% | 1.2% | 96.49 | 0.765 |
| 4 | Ponatinib | 98.6% | 1.4% | 78.23 | 0.534 |
| 5 | Repotrectinib | 98.2% | 1.8% | 84.21 | 0.608 |
| 6 | Crizotinib | 96.8% | 3.2% | 91.39 | 0.581 |
| 7 | Ripretinib | 96.5% | 3.5% | 92.95 | 0.674 |
| 8 | Tivozanib | 95.4% | 4.6% | 92.42 | 0.673 |
| 9 | Selpercatinib | 93.6% | 6.4% | 96.72 | 0.635 |
| 10 | Cabozantinib | 93.2% | 6.8% | 92.73 | 0.751 |
| 11 | Fostamatinib | 90.2% | 9.8% | 96.74 | 0.613 |
| 12 | Erdafitinib | 89.3% | 10.7% | 95.71 | 0.737 |
| 13 | Vandetanib | 88.1% | 11.9% | 95.74 | 0.723 |
| 14 | Nintedanib | 86.2% | 13.8% | 90.23 | 0.608 |
| 15 | Gilteritinib | 82.7% | 17.3% | 88.97 | 0.506 |
| 16 | Pacritinib | 78.6% | 21.4% | 88.64 | 0.452 |
| 17 | Alectinib | 67.2% | 32.8% | 95.49 | 0.651 |
| 18 | Sunitinib | 61.8% | 38.2% | 91.73 | 0.524 |
| 19 | Afatinib | 58.0% | 42.0% | 98.50 | 0.709 |
| 20 | Canertinib | 56.7% | 43.3% | 96.49 | 0.671 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 1.14
- Epithelial log2(TPM+1): 0.59
- Fold change: 0.55
- Status: No significant change
High-confidence drugs
- Nilotinib — inh 98.8% · KISS 50.08
- Dasatinib — inh 99.4% · KISS 41.59
- Selpercatinib — inh 93.6% · KISS 38.24
Selectivity landscape vs inhibition on EPHB1
Each point is one of the 92 approved drugs; color = inhibition % on EPHB1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…